The Duration and Safety of Osteoporosis Treatment

Anabolic and Antiresorptive Therapy

  • Stuart Silverman
  • Bo Abrahamsen

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Rebecca J. Moon, Cyrus Cooper, Nicholas C. Harvey
    Pages 1-16
  3. R. Graham G. Russell, Maria K. Tsoumpra, Michelle A. Lawson, Andrew D. Chantry, Frank H. Ebetino, Michael Pazianas
    Pages 17-36
  4. Erik Fink Eriksen
    Pages 37-59
  5. William D. Leslie, Lisa M. Lix, Suzanne N. Morin
    Pages 61-83
  6. Elisa Torres del Pliego, Daniel Prieto-Alhambra, Adolfo Díez-Perez
    Pages 85-94
  7. Joseph C. Giaconi, C. Travis Watterson
    Pages 107-124
  8. Adele L. Boskey, Marjolein C. H. van der Meulen
    Pages 125-136
  9. Yelena Bogdan, Thomas A. Einhorn
    Pages 137-140
  10. Joy N. Tsai, Mary L. Bouxsein
    Pages 141-152
  11. Joseph M. Lane, Libi Z. Galmer, David S. Wellman, Abigail L. Campbell, Jonathan E. Jo
    Pages 153-162
  12. Parish P. Sedghizadeh, Allan C. Jones
    Pages 163-184
  13. Christian Roux, Karine Briot
    Pages 233-237
  14. Eli Kupperman, Susan V. Bukata
    Pages 255-264
  15. Michael R. McClung
    Pages 279-293
  16. Alexandra Papaioannou, Arnav Agarwal, Sarah Karampatos
    Pages 295-308
  17. Stuart L. Silverman, Bo Abrahamsen
    Pages 321-325
  18. Back Matter
    Pages 327-338

About this book


Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.


Anabolic therapy Antiresorptive therapy Atypical femur fracture Bisphosphonates Bone microarchitecture Drug holiday Fracture risk assessment Osteonecrosis of the jaw Osteoporosis treatment

Editors and affiliations

  • Stuart Silverman
    • 1
  • Bo Abrahamsen
    • 2
  1. 1.Division of Rheumatology, Department of MedicineCedars-Sinai Medical Center; University of California Los Angeles, David Geffen School of MedicineLos AngelesUSA
  2. 2.Institute of Clinical Research; Department of Medicine, Holbæk, DenmarkUniversity of Southern Denmark, Odense Patient Data Explorative Network; Holbæk HospitalOdenseDenmark

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing Switzerland 2016
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-23638-4
  • Online ISBN 978-3-319-23639-1
  • Buy this book on publisher's site